1.07
price up icon5.94%   0.06
after-market Dopo l'orario di chiusura: 1.07
loading
Precedente Chiudi:
$1.01
Aprire:
$1
Volume 24 ore:
2.10M
Relative Volume:
0.88
Capitalizzazione di mercato:
$122.65M
Reddito:
$13.45M
Utile/perdita netta:
$-178.23M
Rapporto P/E:
-0.6485
EPS:
-1.65
Flusso di cassa netto:
$-132.53M
1 W Prestazione:
+2.88%
1M Prestazione:
+1.90%
6M Prestazione:
-47.03%
1 anno Prestazione:
-74.15%
Intervallo 1D:
Value
$1.00
$1.12
Intervallo di 1 settimana:
Value
$0.9301
$1.20
Portata 52W:
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Nome
Fate Therapeutics Inc
Name
Telefono
858.875.1803
Name
Indirizzo
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Dipendente
181
Name
Cinguettio
@fatethx
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
FATE's Discussions on Twitter

Confronta FATE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.07 119.19M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
ONC
Beigene Ltd Adr
228.38 25.07B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.65 109.14B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.27 36.39M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
594.32 56.98B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
71.31 5.39B 0 -153.72M -103.81M -2.00

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-18 Aggiornamento BofA Securities Underperform → Neutral
2024-06-17 Aggiornamento Piper Sandler Neutral → Overweight
2023-03-27 Ripresa Wells Fargo Equal Weight
2023-01-24 Downgrade H.C. Wainwright Buy → Neutral
2023-01-06 Downgrade BMO Capital Markets Outperform → Market Perform
2023-01-06 Downgrade BofA Securities Buy → Underperform
2023-01-06 Downgrade Cowen Outperform → Market Perform
2023-01-06 Downgrade Piper Sandler Overweight → Neutral
2023-01-06 Downgrade Stifel Buy → Hold
2023-01-06 Downgrade Truist Buy → Hold
2023-01-06 Downgrade Wedbush Outperform → Neutral
2023-01-03 Downgrade Guggenheim Buy → Neutral
2022-12-22 Downgrade Oppenheimer Outperform → Perform
2022-12-15 Iniziato Goldman Sell
2022-11-04 Ripresa Cantor Fitzgerald Overweight
2022-10-10 Iniziato Canaccord Genuity Buy
2022-08-18 Ripresa Wells Fargo Overweight
2022-07-28 Iniziato Needham Hold
2022-07-11 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-06-03 Iniziato Robert W. Baird Neutral
2022-02-11 Ripresa BMO Capital Markets Market Perform
2021-12-15 Aggiornamento Wedbush Neutral → Outperform
2021-12-07 Iniziato Cowen Outperform
2021-11-09 Aggiornamento Citigroup Neutral → Buy
2021-08-26 Iniziato Morgan Stanley Equal-Weight
2021-06-07 Aggiornamento H.C. Wainwright Neutral → Buy
2021-05-07 Aggiornamento Wedbush Neutral → Outperform
2021-04-26 Ripresa Jefferies Buy
2021-02-26 Iniziato BofA Securities Buy
2021-02-26 Downgrade Wedbush Outperform → Neutral
2021-02-11 Downgrade Citigroup Buy → Neutral
2021-01-27 Ripresa H.C. Wainwright Neutral
2020-05-13 Iniziato H.C. Wainwright Buy
2020-03-04 Iniziato Barclays Overweight
2020-01-09 Downgrade BMO Capital Markets Outperform → Market Perform
2019-12-30 Reiterato Mizuho Buy
2019-12-09 Aggiornamento Wells Fargo Market Perform → Outperform
2019-11-12 Iniziato SunTrust Buy
2019-11-06 Downgrade Wells Fargo Outperform → Market Perform
2019-10-01 Iniziato Stifel Buy
2019-08-09 Iniziato BTIG Research Buy
2019-07-22 Iniziato Cantor Fitzgerald Overweight
2019-07-12 Iniziato Oppenheimer Outperform
2019-06-13 Iniziato Mizuho Buy
2019-06-07 Iniziato ROTH Capital Neutral
2019-05-31 Iniziato Guggenheim Buy
2019-05-24 Ripresa Citigroup Buy
2019-03-28 Iniziato SVB Leerink Outperform
2019-01-03 Downgrade Stephens Overweight → Equal-Weight
2018-11-05 Iniziato Jefferies Buy
2018-08-01 Iniziato Citigroup Buy
2018-03-06 Downgrade H.C. Wainwright Buy → Neutral
Mostra tutto

Fate Therapeutics Inc Borsa (FATE) Ultime notizie

pulisher
03:42 AM

Robert W. Baird Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $4.00 - Defense World

03:42 AM
pulisher
03:42 AM

Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World

03:42 AM
pulisher
03:10 AM

Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World

03:10 AM
pulisher
03:10 AM

What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World

03:10 AM
pulisher
May 16, 2025

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN

May 16, 2025
pulisher
May 16, 2025

Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

May 16, 2025
pulisher
May 15, 2025

Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Fate Therapeutics (FATE) Faces Significant Price Target Reductio - GuruFocus

May 15, 2025
pulisher
May 14, 2025

FATE Stock Update: Analyst Lowers Price Target, Maintains Neutra - GuruFocus

May 14, 2025
pulisher
May 14, 2025

4 Analysts Assess Fate Therapeutics: What You Need To Know - Benzinga

May 14, 2025
pulisher
May 14, 2025

Barclays Adjusts Fate Therapeutics (FATE) Price Target Amid Q1 R - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Baird Revises Fate Therapeutics (FATE) Price Target Post-Q1 Resu - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FATE Therapeutics Exceeds Revenue Estimates with Strong CAR T-Ce - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Fate Therapeutics: Q1 Earnings Snapshot - CT Insider

May 14, 2025
pulisher
May 14, 2025

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts

May 14, 2025
pulisher
May 13, 2025

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times

May 13, 2025
pulisher
May 13, 2025

FATE THERAPEUTICS INC SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

What Is Going On With Fate Therapeutics Inc (NASDAQ: FATE)? - Stocksregister

May 13, 2025
pulisher
May 13, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LP - Defense World

May 13, 2025
pulisher
May 12, 2025

Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

May 12, 2025
pulisher
May 11, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by MetLife Investment Management LLC - Defense World

May 11, 2025
pulisher
May 10, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Wells Fargo & Company MN - Defense World

May 10, 2025
pulisher
May 08, 2025

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha

May 08, 2025
pulisher
May 07, 2025

Fate Therapeutics Inc (NASDAQ: FATE) Drops -18.14 Percent In Recent Trading, What Questions Do You Have? - Stocksregister

May 07, 2025
pulisher
May 05, 2025

Fate Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 02, 2025
pulisher
May 02, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages - Defense World

May 02, 2025
pulisher
May 01, 2025

Fate Therapeutics Inc [FATE] Records 50-Day SMA of $1.0480 - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

LPL Financial LLC Buys New Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Uncovering the Potential of Fate Therapeutics Inc (FATE) Stock - investchronicle.com

Apr 30, 2025
pulisher
Apr 30, 2025

There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Fate Therapeutics to Present Clinical and Preclinical Data at ASGCT 28th Annual Meeting - Nasdaq

Apr 29, 2025
pulisher
Apr 29, 2025

Was anything negative for Fate Therapeutics Inc (FATE) stock last session? - uspostnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

Fate Therapeutics Announces Five Presentations on - GlobeNewswire

Apr 29, 2025
pulisher
Apr 28, 2025

The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo

Apr 27, 2025
pulisher
Apr 26, 2025

Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

FATE Shares Experience Decline in Value - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News

Apr 22, 2025
pulisher
Apr 21, 2025

Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com

Apr 21, 2025
pulisher
Apr 19, 2025

Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN

Apr 16, 2025

Fate Therapeutics Inc Azioni (FATE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Fate Therapeutics Inc Azioni (FATE) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Bressi Jerome Charles
See Remarks
Jan 10 '25
Sale
1.55
5,980
9,269
270,203
TAHL CINDY
See Remarks
Jan 10 '25
Sale
1.55
5,654
8,764
336,707
Valamehr Bahram
President and CEO
Jan 10 '25
Sale
1.54
8,705
13,406
349,364
$1.28
price down icon 1.54%
$30.93
price up icon 7.58%
$565.63
price up icon 0.69%
$3.99
price up icon 5.28%
$285.31
price up icon 0.67%
$71.31
price up icon 2.56%
Capitalizzazione:     |  Volume (24 ore):